Welcome to our dedicated page for Charles Riv Labs Intl news (Ticker: CRL), a resource for investors and traders seeking the latest updates and insights on Charles Riv Labs Intl stock.
News about Charles River Laboratories International, Inc. (NYSE: CRL) focuses on its role in research and development in biotechnology and its activities as a contract research and manufacturing partner to pharmaceutical, biotechnology, government, and academic clients. Company updates often highlight how Charles River’s research models, discovery and safety assessment services, and manufacturing solutions support the discovery, early-stage development, and safe manufacture of new therapies.
Investors and industry followers can expect frequent news on strategic transactions and partnerships. Recent announcements include planned acquisitions such as K.F. (Cambodia) Ltd., a provider of non-human primates for regulatory-required biomedical, pharmaceutical, and toxicological research, and PathoQuest SAS, a provider of next-generation sequencing solutions for manufacturing quality-control testing. The company also reports collaborations, for example with The Francis Crick Institute on antibody-drug conjugate discovery and with X-Chem, Inc. to expand hit identification capabilities using DNA-encoded library technology.
Charles River’s news flow also covers scientific and operational initiatives. The company has announced the creation of a Scientific Advisory Board led by Dr. Namandjé N. Bumpus to advance New Approach Methodologies (NAMs) and reduce reliance on animal testing, as well as the expansion of its Cell & Gene Therapy Incubator Program to support early-stage advanced therapy developers and enabling technology companies. Updates on its strategic review, portfolio refinement, restructuring initiatives, and capital deployment plans provide additional context on long-term positioning and financial priorities.
Governance and leadership developments are another recurring theme, such as the planned CEO succession and the appointment of a Chief Scientific and Innovation Officer. Earnings releases and conference presentations offer insight into demand trends across the Research Models and Services, Discovery and Safety Assessment, and Manufacturing Solutions segments. For readers tracking CRL, this news page brings together these earnings updates, transaction announcements, scientific collaborations, and strategic milestones in one place.
Charles River Laboratories (NYSE: CRL) will present at the 41st Annual J.P. Morgan Healthcare Conference on January 10 at 10:30 a.m. PST (1:30 p.m. EST). The presentation will cover strategic focuses, business developments, and recent trends. Investors can access a live webcast through the Investor Relations section of their website, with a replay available for two weeks afterward. Charles River provides vital products and services to pharmaceutical and biotechnology firms, aiding in research and drug development.
Arlington Capital Partners has acquired Charles River Laboratories' Avian Vaccine Services business, establishing a new entity called AVS Bio. This company will operate independently and cater to the biologic manufacturing market. AVS Bio is a leader in supplying specific pathogen-free eggs and laboratory products essential for vaccine development and manufacturing. With approximately 250 employees across over 20 facilities in the US and Europe, AVS Bio aims to expand through new product development and strategic acquisitions. The acquisition signals Arlington's focus on mission-critical inputs in the biologic sector.
Charles River Laboratories (NYSE: CRL) has re-appointed Dr. Craig B. Thompson to its Board of Directors. Dr. Thompson, a former President and CEO of Memorial Sloan-Kettering Cancer Center, served on Charles River's board from 2013 to 2018. His expertise in immuno-oncology and leadership in healthcare will enhance the board's strategic direction. Dr. Thompson aims to support Charles River's mission in drug research and development. His extensive background includes leadership roles in prominent medical institutions and significant contributions to cancer research.
Charles River Laboratories (NYSE: CRL) has launched the Endosafe® Nexus 200™, a robotic endotoxin testing system designed to enhance laboratory productivity. This system enables efficient testing of undiluted and complex samples, leveraging Endosafe Limulus Amebocyte Lysate (LAL) cartridge technology. Key benefits include a reduction in product lead times by 60-70%, minimized human error, and improved data management through integration with Laboratory Information Management Systems (LIMS). This launch addresses the growing demand for high-throughput automated solutions in pharmaceutical manufacturing.
Charles River Laboratories (NYSE: CRL) has launched its first Charles River Accelerator and Development Lab (CRADL) in Chicago, enhancing contract vivarium space for the biopharmaceutical sector in Illinois. Located in Fulton Market, this facility supports both emerging and established companies by providing on-demand laboratory space, fostering rapid project initiation. The CRADL-Explora Vivarium Network now encompasses 28 facilities across key locations, providing over 380,000 square feet of rental capacity, supporting the growth of the biotech ecosystem.
Charles River Laboratories (NYSE: CRL) will present at two significant investor conferences: the Jefferies 2022 London Healthcare Conference on November 16 at 10:20 a.m. GMT and the Evercore ISI 5th Annual HealthCONx Conference virtually on November 30 at 9:40 a.m. ET. Management will discuss the company’s strategic focus and recent business developments. Live webcasts will be available on the Investor Relations section of Charles River's website, with replays accessible for two weeks post-event.
Charles River Laboratories (NYSE: CRL) announced their participation at Neuroscience 2022, where they will present 23 scientific posters on neuroscience advancements. Key presentations include studies on gene therapy, biological markers in Alzheimer's, and Huntington's disease neuronal models. The event takes place from November 12-16 in San Diego, CA, featuring discussions on innovative drug therapies and approaches to neurodegenerative disorders. A notable quote indicates their support of 95% of FDA-approved neuroscience therapies in the last five years.
Charles River Laboratories (NYSE: CRL) has expanded its cell therapy contract development and manufacturing facility in Memphis, Tennessee. The facility now includes nine new processing suites, enhancing its capacity for clinical and commercial cell therapy production. These suites maintain compliance with GMP and international standards, featuring advanced containment designs and high-volume production capabilities. This expansion follows the facility's EMA approval to produce allogeneic cell therapy products, enabling quicker commercialization of transformative medicines.
Charles River Laboratories (CRL) reported third-quarter 2022 revenue of $989.2 million, a 10.4% increase from the prior year. GAAP earnings per share (EPS) fell 6.5% to $1.88, while non-GAAP EPS decreased 2.6% to $2.63.
Key factors included revenue growth in the Discovery and Safety Assessment segment, although divestitures and foreign currency effects reduced overall growth. The company announced plans to divest its Avian Vaccine business for approximately $170 million, projected to decrease revenue by $80 million in 2023. 2022 revenue growth guidance is narrowed to 10.0%-11.0%.
Charles River Laboratories (NYSE:CRL) announced the launch of a new digital donor experience to enhance donor engagement across its HemaCare Donor Centers in four US locations: Northridge, CA; Bothell, WA; Memphis, TN; and Lowell, MA. The digital app allows users to pre-qualify for donations and self-schedule appointments online. This initiative aims to streamline operations, increase donor conversions, and foster a diverse donor pool. HemaCare Donor Centers, FDA-registered and AABB-certified, provide crucial materials for medical research and therapies, offering anonymity and compensation for donors.